Marking Cycle Pharma’s first foray into oncology, Phyrago becomes the company’s ninth commercial product and expands its mission to support patients with chronic and complex conditions.
PPIs And H2RAs For Leukaemia Treatment | 23/07/2025 | By Darshana | 514
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy